Germany Biotechnology Market 2025-2035

Description

List of Tables

Germany Biotechnology Market Size, Share & Trends Analysis Report by Product (Instruments & Equipment, Reagents & Consumables, and Software & Services), by Technology (DNA Sequencing & Genomics, Cell Culture Technology, Nano biotechnology, Fermentation Technology, Chromatography & Separation, Tissue Engineering & Regenerative Medicine, CRISPR & Gene Editing, Proteomics & Protein Engineering, Bioinformatics, and Others) and by Application (Healthcare & Medical, Agriculture & Food, Industrial / Environmental and Marine Biotechnology), Forecast Period (2026-2035)

Industry Overview

Germany biotechnology market was valued at $54.8 billion in 2025 and is projected to reach $100.7 billion by 2035, growing at a CAGR of 6.3% during the forecast period (2026-2035). Germany's biotechnology market is driven by a strong infrastructure of research facilities and increasing contributions from the private sector. Companies are focusing on sophisticated applications in human and veterinary medicine, agriculture and animal feed, and industrial processes. The growth is propelled in part by the continuing need for new and innovative technologies that enhance medical treatments and more efficient production processes. German companies continue to solidify collaboration between academia and industry. This supports innovation, allowing more rapid uptake of new biotechnologies.

Market Dynamics

Expansion of Industrial Biotech

Industrial biotechnology in Germany is experiencing consistent growth with the nation's firm focus on innovation and sustainability. The firms are proactively engaged in formulating bio-based products to substitute traditional petrochemical-based substances. For instance, Evonik Industries AG offers innovative microbial fermentation technologies for producing specialty chemicals with reduced carbon impacts. Such innovations reduce dependence on fossil resources and respond to Europe's climate-neutral ambitions. The technology additionally supports the scale-up production of enzymes, amino acids, and other specialized high-value products. The growing partnership between research institutions and industrial companies continues to enhance the speed of innovative work. These developments put Germany at the forefront of biotechnology based on circular economy concepts.

Increasing Emphasis on Agricultural Biotechnology

Agricultural biotechnology is emerging as a key area of growth in Germany, especially as farmer is endangered by climate change and food security globally. The industry is concerned with developing robust crop varieties and green crop protection. For instance, Bayer AG, Leverkusen-based, is at the forefront of developing genetically modified seeds and precision farming technologies. The technologies are designed for yield improvement, pest resistance, and reduced use of chemical pesticides. Biotechnology-based farming also favors sustainable agriculture practices. Increased R&D spending is further fueling product pipelines in this industry. Such a trend is indicative of Germany's strategic orientation toward integrating biotechnology with contemporary agricultural systems to secure long-term food security.

Market Segmentation

Based on the product, the market is segmented into instruments & equipment, reagents & consumables, and software & services.
Based on technology, the market is segmented into DNA sequencing & genomics, cell culture technology, nano biotechnology, fermentation technology, chromatography & separation, tissue engineering & regenerative medicine, CRISPR & gene editing, proteomics & protein engineering, bioinformatics, and others.
Based on the application, the market is segmented into healthcare & medical, agriculture & food, industrial/environmental, and marine biotechnology.

Instruments & Equipment Segment to Lead the Market with the Largest Share

The demand for biotechnology instruments and equipment is a primary driver in this segment of the German market. The need for high-performance laboratory systems, bioreactors, and analytical instruments is on the rise for both research purposes and industrial production. For instance, Sartorius AG, located in Gottingen, provides advanced bioprocessing equipment for developers of pharmaceutical products. This equipment enables researchers to optimize cell culture, purification, and scaling up biopharmaceutical production. The focus on precision and adhering to international guidelines encourages the use of these instruments made in Germany. This sector is still drawing investment as research institutions and businesses upgrade their facilities.

Healthcare & Medical: A Key Segment in Market Growth

Healthcare and medical use of biotechnology is a strong area of the biotech market in Germany. There are more chronic diseases, and the push for better therapies is prompting investment in this area of biotechnology. For instance, Mainz's BioNTech SE has achieved global notoriety for its mRNA-based medicine and represents the power of German innovation in the health space. More companies are investing in immunotherapies and personalized medicines to address unmet medical needs. The German healthcare system that supports clinical adoption accelerates biotechnological solutions. This segment continues to form the core of the market's long-term growth.

Market Players Outlook

The major companies operating in the Germany biotechnology market include Bayer AG, Merck KGaA, QIAGEN N.V., Novartis AG, and Boehringer Ingelheim International GmbH, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In August 2025, Ethris GmbH, a clinical-stage biotech company in next-generation RNA therapeutics and vaccines, revealed that the first patient had been dosed in a Phase 2a clinical trial evaluating ETH47, Ethris' lead mRNA antiviral candidate. The trial determines the efficacy of intranasal ETH47 in alleviating asthma symptoms after a rhinovirus challenge in subjects with asthma.
In February 2023, Evotec SE announced that the Company has extended and enlarged its integrated multi-target drug discovery collaboration with data-driven biotech creation company, Related Sciences, to continue developing its combined portfolio of drug development candidates through 2030, driving Evotec's industry-leading capabilities across the entire R&D continuum. To support the expanding portfolio in excess of 15 discovery-stage candidates, the partners are broadening the collaboration to encompass Evotec's leading-edge capabilities in covalent inhibitor discovery.

The Report Covers:

Market value data analysis of 2025 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the Germany biotechnology market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2022668

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Germany Biotechnology Market Sales Analysis - Product | Technology | Application | ($ Million)
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Germany Biotechnology Industry Trends
- 2.2.2. Market Recommendations

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Germany Biotechnology Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Germany Biotechnology Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For Germany Biotechnology Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - Germany Biotechnology Market Revenue and Share by Manufacturers
Personal Care Ingredients Comparison Analysis
4.2. Key Company Analysis
- 4.2.1. Bayer AG
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Boehringer Ingelheim International GmbH
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Novartis AG
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Merck KGaA
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. QIAGEN N.V.
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Germany Biotechnology Market Sales Analysis by Product ($ Million)

5.1. Instruments & Equipment
5.2. Reagents & Consumables
5.3. Software & Services

6. Germany Biotechnology Market Sales Analysis by Technology ($ Million)

6.1. DNA Sequencing & Genomics
6.2. Cell Culture Technology
6.3. Nano Biotechnology
6.4. Fermentation Technology
6.5. Chromatography & Separation
6.6. Tissue Engineering & Regenerative Medicine
6.7. CRISPR & Gene Editing
6.8. Proteomics & Protein Engineering
6.9. Bioinformatics
6.10. Others

7. Germany Biotechnology Market Sales Analysis by Application ($ Million)

7.1. Healthcare & Medical
7.2. Agriculture & Food
7.3. Industrial / Environmental
7.4. Marine Biotechnology

8. Company Profiles

8.1. 4SC AG
- 8.1.1. Quick Facts
- 8.1.2. Company Overview
- 8.1.3. Product Portfolio
- 8.1.4. Business Strategies
8.2. Aicuris Anti-infective Cures AG
- 8.2.1. Quick Facts
- 8.2.2. Company Overview
- 8.2.3. Product Portfolio
- 8.2.4. Business Strategies
8.3. Bayer AG
- 8.3.1. Quick Facts
- 8.3.2. Company Overview
- 8.3.3. Product Portfolio
- 8.3.4. Business Strategies
8.4. Biofrontera AG
- 8.4.1. Quick Facts
- 8.4.2. Company Overview
- 8.4.3. Product Portfolio
- 8.4.4. Business Strategies
8.5. BioNTech SE
- 8.5.1. Quick Facts
- 8.5.2. Company Overview
- 8.5.3. Product Portfolio
- 8.5.4. Business Strategies
8.6. Boehringer Ingelheim International GmbH
- 8.6.1. Quick Facts
- 8.6.2. Company Overview
- 8.6.3. Product Portfolio
- 8.6.4. Business Strategies
8.7. Cardior Pharmaceuticals GmbH
- 8.7.1. Quick Facts
- 8.7.2. Company Overview
- 8.7.3. Product Portfolio
- 8.7.4. Business Strategies
8.8. Curetis GmbH
- 8.8.1. Quick Facts
- 8.8.2. Company Overview
- 8.8.3. Product Portfolio
- 8.8.4. Business Strategies
8.9. CureVac N.V.
- 8.9.1. Quick Facts
- 8.9.2. Company Overview
- 8.9.3. Product Portfolio
- 8.9.4. Business Strategies
8.10. emp BIOTECH GmbH
- 8.10.1. Quick Facts
- 8.10.2. Company Overview
- 8.10.3. Product Portfolio
- 8.10.4. Business Strategies
8.11. Evotec SE
- 8.11.1. Quick Facts
- 8.11.2. Company Overview
- 8.11.3. Product Portfolio
- 8.11.4. Business Strategies
8.12. Heidelberg Pharma AG
- 8.12.1. Quick Facts
- 8.12.2. Company Overview
- 8.12.3. Product Portfolio
- 8.12.4. Business Strategies
8.13. Immatics Biotechnologies GmbH
- 8.13.1. Quick Facts
- 8.13.2. Company Overview
- 8.13.3. Product Portfolio
- 8.13.4. Business Strategies
8.14. InflaRx N.V.
- 8.14.1. Quick Facts
- 8.14.2. Company Overview
- 8.14.3. Product Portfolio
- 8.14.4. Business Strategies
8.15. Leukocare AG
- 8.15.1. Quick Facts
- 8.15.2. Company Overview
- 8.15.3. Product Portfolio
- 8.15.4. Business Strategies
8.16. Medigene AG
- 8.16.1. Quick Facts
- 8.16.2. Company Overview
- 8.16.3. Product Portfolio
- 8.16.4. Business Strategies
8.17. Merck KGaA
- 8.17.1. Quick Facts
- 8.17.2. Company Overview
- 8.17.3. Product Portfolio
- 8.17.4. Business Strategies
8.18. Miltenyi Biotec B.V. & Co. KG
- 8.18.1. Quick Facts
- 8.18.2. Company Overview
- 8.18.3. Product Portfolio
- 8.18.4. Business Strategies
8.19. Novartis AG
- 8.19.1. Quick Facts
- 8.19.2. Company Overview
- 8.19.3. Product Portfolio
- 8.19.4. Business Strategies
8.20. Oncgnostics GmbH
- 8.20.1. Quick Facts
- 8.20.2. Company Overview
- 8.20.3. Product Portfolio
- 8.20.4. Business Strategies
8.21. Pentixapharm Holding AG
- 8.21.1. Quick Facts
- 8.21.2. Company Overview
- 8.21.3. Product Portfolio
- 8.21.4. Business Strategies
8.22. QIAGEN N.V.
- 8.22.1. Quick Facts
- 8.22.2. Company Overview
- 8.22.3. Product Portfolio
- 8.22.4. Business Strategies
8.23. R-Biopharm AG
- 8.23.1. Quick Facts
- 8.23.2. Company Overview
- 8.23.3. Product Portfolio
- 8.23.4. Business Strategies
8.24. Sartorius AG
- 8.24.1. Quick Facts
- 8.24.2. Company Overview
- 8.24.3. Product Portfolio
- 8.24.4. Business Strategies
8.25. Secarna Pharmaceuticals GmbH & Co. KG
- 8.25.1. Quick Facts
- 8.25.2. Company Overview
- 8.25.3. Product Portfolio
- 8.25.4. Business Strategies
8.26. Wacker Chemie AG
- 8.26.1. Quick Facts
- 8.26.2. Company Overview
- 8.26.3. Product Portfolio
- 8.26.4. Business Strategies